• PepGen published its FREEDOM2-DM1 10 mg/kg presentation, reporting Phase 2 results for PGN-EDODM1 in myotonic dystrophy type 1.
• Mean splicing correction reached 46.5% at week 13 among six treated patients, versus 6.8% with placebo.
• Hand-opening time improved by 4.3 seconds at week 13 and 3.9 seconds at week 16 in the 10 mg/kg group.
• All adverse events were mild or moderate, with no serious adverse events or treatment discontinuations in the study.
• The 12.5 mg/kg cohort is fully enrolled, with participants having received up to three doses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.